DDInter1293 DDInter927
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
Nilotinib {u} (Compound) binds {v} (Gene) CA7
Nilotinib {u} (Compound) upregulates {v} (Gene) HERPUD1
Nilotinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Nilotinib {u} (Compound) downregulates {v} (Gene) BNIP3
Nilotinib {u} (Compound) causes {v} (Side Effect) Lymphopenia
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methysergide
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Nilotinib (Compound) treats hematologic cancer (Disease)
Nilotinib (Compound) binds CA7 (Gene)
Nilotinib (Compound) upregulates HERPUD1 (Gene)
Nilotinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Nilotinib (Compound) downregulates BNIP3 (Gene)
Nilotinib (Compound) causes Lymphopenia (Side Effect)
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Methysergide